- Home
- MNR vs GENB Comparison
MNR vs GENB Comparison
Compare MNR & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MNR | GENB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2023 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MNR | GENB |
|---|---|---|
| Price | $12.63 | $16.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $18.00 | ★ $23.20 |
| AVG Volume (30 Days) | 299.7K | ★ 536.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 14.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,175,390,000.00 | N/A |
| Revenue This Year | $34.60 | N/A |
| Revenue Next Year | $2.35 | $16.58 |
| P/E Ratio | $33.24 | ★ N/A |
| Revenue Growth | ★ 21.22 | N/A |
| 52 Week Low | $10.46 | $11.00 |
| 52 Week High | $15.02 | $18.18 |
Technical Indicators
Market Signals| Indicator | MNR | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 40.27 | N/A |
| Support Level | $12.65 | N/A |
| Resistance Level | $12.79 | N/A |
| Average True Range (ATR) | 0.26 | 0.00 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 20.35 | 0.00 |
Price Performance
Historical ComparisonAbout MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas and the panhandle of Texas; the San Juan Basin region of New Mexico and Colorado; and the Permian Basin region of West Texas. The company is organized and managed as a single reportable segment, which is the exploration and production of oil, natural gas and NGLs (E&P Segment).
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.